10-Year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology

Journal of Urology

Volumn 172, Issue 6 I, 2004, Pages 2232-2238

  Critz, Frank A ^a   Levinson, Keith ^b  

^a Radiotherapy Clinics of Georgia   (United States)

^b Georgia Urology   (United States)

Author keywords

Brachytherapy; Prostatic neoplasms; Radiotherapy

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 8644265042     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000144033.61661.31     Document Type: Article

References (23)

1. Critz, F. A., Williams, W. H., Levinson, A. K., Benton, J. B., Holladay, C. T. and Schnell, F. J., Jr.: Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol, 164: 738, 2000
2. Steinberg, D. M., Sauvageot, J., Piantadosi, S. and Epstein, J. I.: Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol, 21: 566, 1997
3. Gretzer, M. B., Trock, B. J., Han, M. and Walsh, P. C.: A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology Criteria. J Urol, 168: 1419, 2002
4. Amling, C. L., Bergstralh, E. J., Blute, M. L., Slezak, J. M. and Zincke, H.: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol, 165: 1146, 2001
5. Freedland, S. J., Sutter, M. E., Dorey, F. and Aronson, W. J.: Defining the ideal outpoint for determining PSA recurrence after radical prostatectomy. Urology, 61: 365, 2003
6. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys, 37: 1035, 1997
7. Critz, F. A.: A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol, 167: 1310, 2002
8. Critz, F. A.: Time to achieve prostate specific antigen nadir 0.2 ng./ml. following simultaneous irradiation of prostate cancer. J Urol, 168: 2434, 2002
9. Hanlon, A. L., Pinover, W. H., Horwitz, E. M. and Hanks, G. E.: Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys, 50: 845, 2001
10. Cavanagh, W., Blasko, J. C., Grimm, P. D. and Sylvester, J. E.: Transient elevation of serum prostate-specific antigen following (125)17(103) brachytherapy for localized prostate cancer. Sem Urol Oncol, 8: 160, 2000
11. Critz, F. A., Williams, W. H., Levinson, A. K., Benton, J. B., Schnell, F. J., Holladay, C. T. et al: Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. J Urol, 170: 1864, 2003
12. Vicini, F. A., Kestin, L. L. and Martinez, A. A.: The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys, 45: 553, 1999
13. Connell, P. P., Ignacio, L., McBride, R. B., Weichselbaum, R. R. and Vijayakumar, S.: Caution in interpreting biochemical control rates after treatment of prostate cancer: length of follow-up influences results. Urology, 54: 875, 1999
14. Coen, J. J., Chung, C. S., Shipley, W. U. and Zietman, A. L.: Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis. Int J Radiat Oncol Biol Phys, 57: 621, 2003
15. Ward, J. F., Blute, M. L., Slezak, J., Bergstralh, E. J. and Zincke, H.: The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol, 170: 1872, 2003
16. Khan, M. A., Han, M., Partin, A. W., Epstein, J. I. and Walsh, P. C.: Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology, 62: 86, 2003
17. Zeitlin, S. I., Sherman, J., Raboy, A., Lederman, G. and Albert, P.: High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol, 160: 91, 1998
18. Iversen, P., Rasmussen, F. and Holm, H. H.: Long-term results of ultrasonically guided implantation of 125-1 seeds combined with external irradiation in localized prostatic cancer. Scand J Urol Nephrol Suppl, 138: 109, 1991
19. Howard, A., Wallner, K., Han, B., Dominitz, J., Schneider, B., Sutlief, S. et al: Clinical course and dosimetry of rectal fistulas after prostate brachytherapy. J Brachytherapy Int, 17: 37, 2001
20. Blasko, J. C., Ragde, H., Luse, R. W., Sylvester, J. E., Cavanagh, W. and Grimm, P. D.: Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am, 23: 633, 1996
21. Gelblum, D. Y., Potters, L., Ashley, R., Waldbau, R., Wang, X. H. and Leibel, S.: Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys, 45: 59, 1999
22. Grimm, P. D., Blasko, J. D., Ragde, H., Sylvester, J. and Clarke, D.: Does brachytherapy have a role in the treatment of prostate cancer? Hematol/Oncol Clin North Am, 10: 653, 1996
23. Hu, J. C., Gold, K. F., Pashos, C. L., Mahta, S. S. and Litwon, M. S.: Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol, 21: 401, 2003